Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

BACKGROUND. Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Leichman, Lawrence, Groshen, Susan, O’Neil, Bert H., Messersmith, Wells, Berlin, Jordan, Chan, Emily, Leichman, Cynthia G., Cohen, Steven J., Cohen, Deirdre, Lenz, Heinz-Josef, Gold, Philip, Boman, Bruce, Fielding, Anitra, Locker, Gershon, Cason, Ronald C., Hamilton, Stan R., Hochster, Howard S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2016
Schlagworte:
Gastrointestinal Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746089/
https://ncbi.nlm.nih.gov/pubmed/26786262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0319
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge